Nitroso–Redox Balance in the Cardiovascular System
Author:
- Joshua M. HareJHJoshua M. Hare
- 11 November 2004
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (20) , 2112-2114
Abstract
In this issue of the Journal, Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black.1 The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of approximately 45 percent, leading to an early termination of the study.Keywords
This publication has 14 references indexed in Scilit:
- Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart FailureNew England Journal of Medicine, 2004
- Blood traffic controlNature, 2004
- Red Blood Cell Nitric Oxide as an Endocrine VasoregulatorCirculation, 2004
- Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implicationsThe Journal of Physiology, 2004
- Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-toleranceJournal of Clinical Investigation, 2004
- Nitric oxide and excitation–contraction couplingJournal of Molecular and Cellular Cardiology, 2003
- NitrosylationCell, 2001
- Activation of the Cardiac Calcium Release Channel (Ryanodine Receptor) by Poly-S-NitrosylationScience, 1998
- Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.Journal of Clinical Investigation, 1996
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991